Genmab-AbbVie Epcoritamab Phase 3 Trial Misses Primary OS Endpoint in U.S. for Relapsed/Refractory DLBCL

Genmab A/S (NASDAQ: GMAB) and AbbVie Inc. (NYSE: ABBV) announced on July 23, 2026 that the Phase 3 EPCORE DLBCL-1 study evaluating epcoritamab monotherapy versus investigator’s choice chemoimmunotherapy failed to meet its primary endpoint in the United States. The trial, which compared the T-cell engaging bispecific antibody against standard regimens in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplantation, did not demonstrate statistically significant improvement in overall survival (OS)—the sole primary endpoint for the U.S. regulatory region.

Clinical Trial Overview

Drug Profile & Current Status

• Epcoritamab: T-cell engaging bispecific antibody targeting CD3 (T-cell receptor) and CD20 (B-cell marker), designed to redirect T-cells to eliminate malignant B-cells
• Current Approval: Granted under FDA’s accelerated approval pathway for adult patients with R/R DLBCL, not otherwise specified (NOS), including DLBCL arising from indolent lymphoma and high-grade B-cell lymphoma, after two or more lines of systemic therapy
• Mechanism Advantage: Subcutaneous administration offers convenience over intravenous therapies, with potential for outpatient treatment
• Global Development: Part of Genmab and AbbVie’s broader collaboration to develop epcoritamab across multiple B-cell malignancies

Regional Endpoint Differences

• U.S. Regulatory Framework: FDA required overall survival as the confirmatory endpoint for converting accelerated approval to full approval
• Other Regions: Trial included prespecified primary endpoints that differ by region, potentially including progression-free survival (PFS) or other surrogate endpoints acceptable to non-U.S. regulatory authorities
• Statistical Implications: Failure to demonstrate OS benefit in the U.S. population may impact the drug’s commercial trajectory in the world’s largest pharmaceutical market
• Accelerated Approval Risk: Results raise questions about potential accelerated approval withdrawal if confirmatory evidence fails to verify clinical benefit

Market Impact & Strategic Implications

• Commercial Exposure: DLBCL represents one of the most common forms of non-Hodgkin lymphoma, with approximately 25,000 new cases annually in the U.S. alone
• Competitive Landscape: Epcoritamab competes with other CD20-targeting therapies, CAR-T products (Yescarta, Breyanzi), and emerging bispecific antibodies (mosunetuzumab, glofitamab)
• Partnership Dynamics: Genmab retains U.S. commercial rights while AbbVie holds ex-U.S. rights, creating asymmetric financial impact from the trial outcome
• Investment Reaction: Genmab shares are expected to face pressure following the announcement, while AbbVie’s diversified portfolio may provide insulation from single-product setbacks

Forward Path Considerations

• Regulatory Engagement: Companies will likely engage with FDA to discuss potential pathways forward, including analysis of secondary endpoints or subgroup populations
• Global Strategy: Success in non-U.S. regions could still support international commercial expansion, depending on regional endpoint results
• Pipeline Diversification: Both companies maintain robust oncology pipelines, with epcoritamab being evaluated in earlier lines of therapy and combination regimens
• Clinical Practice Impact: Despite OS results, clinicians may continue using epcoritamab based on response rates, safety profile, and patient convenience factors

Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial outcomes, regulatory pathways, and commercial expectations. Actual results may differ due to regulatory decisions, competitive dynamics, and evolving clinical practice patterns.-Fineline Info & Tech